Ovulation induction and controlled ovarian stimulation using letrozole gonadotropin combination: A single center retrospective cohort study
article
OA: closed
CC0
AI-generated summary
This retrospective cohort study evaluated the efficacy and safety of combining letrozole with gonadotropins for ovulation induction and controlled ovarian stimulation at a single center.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
ObjectiveTo assess the effect of letrozole in combination with low dose gonadotropins for ovulation induction in anovulatory infertility from polycystic ovary syndrome (PCOS) and controlled ovarian stimulation for endometriosis, and unexplained infertility patients.Study designRetrospective cohort study in a setting of private Reproductive Endocrinology and Infertility Clinic affiliated with the University. Three hundred couples (650 cycles) requiring OI/COS for PCOS (92 patients, 195 cycles), endometriosis (89 patients, 217 cycles), and unexplained infertility (119 patients, 238 cycles). Patients received 2.5mg or 5mg letrozole for 5days (D3-D7) and recombinant follicle-stimulating hormone on alternating D3-D7 and human menopausal gonadotropin-highly purified alternating D5-D10 until growth of ideally 2 mature follicles. Ovulation was triggered with 10,000 IU of HCG. Maximum number of cycles per patient was four.ResultsMain outcome measures were clinical pregnancy rates, multiple order pregnancy rates, miscarriage rates, number of follicles and endometrial thickness on the day of HCG administration. The cumulative incidence of pregnancy was estimated as 35% (95%CI: 29%-41%) overall and was highest in patients with PCOS (36.6%), followed by unexplained infertility (34.6%) and endometriosis (32.5%). The pregnancy rates per cycle in PCOS, endometriosis and unexplained infertility patients were 17%, 13.2% and 17.2% respectively, no statistically significant difference between the groups. There were three twin pregnancies in PCOS, and one in unexplained infertility group. Monofolliculogenesis was noted in 48% of patients.Conclusion(s)Letrozole-low dose gonadotropins combination appears to be effective across different causes of infertility for superovulation. The letrozole-low dose gonadotropin combination resulted in high rate of monofolliculogenesis, low occurrence of multiple gestations and no case of OHSS or cycle cancellation.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Expression of Concern: Randomized comparison of superovulation with letrozole vs. clomiphene citrate in an IUI program for women with recently surgically treated minimal to mild endometriosis 2011
- The Use of Aromatase Inhibitors for Ovulation Induction and Superovulation 2013
- Cost-effectiveness of aromatase inhibitor co-treatment for controlled ovarian stimulation 2006
References (41)
- Cost-effectiveness of aromatase inhibitor co-treatment for controlled ovarian stimulation via openalex
- Expression of Concern: Randomized comparison of superovulation with letrozole vs. clomiphene citrate in an IUI program for women with recently surgically treated minimal to mild endometriosis via openalex
- The Use of Aromatase Inhibitors for Ovulation Induction and Superovulation via openalex
- W1995071598 via openalex
- W2015849507 via openalex
- W2019567358 via openalex
- W2041274555 via openalex
- W2046385598 via openalex
- W2047530251 via openalex
- W2047730979 via openalex
- W2049892039 via openalex
- W2055756548 via openalex
- W2064102998 via openalex
- W2064686723 via openalex
- W2065832162 via openalex
- W2086050129 via openalex
- W2090167590 via openalex
- W2098534461 via openalex
- W2100306033 via openalex
- W2113789770 via openalex
- W2115337926 via openalex
- W2135998296 via openalex
- W2140825345 via openalex
- W2144550387 via openalex
- W2150299688 via openalex
- W2150825284 via openalex
- W2158299014 via openalex
- W2159902645 via openalex
- W2165232862 via openalex
- W2167729502 via openalex
- W2186218348 via openalex
- W2304227435 via openalex
- W2326256880 via openalex
- W2481420451 via openalex
- W4245035534 via openalex
- W6660840855 via openalex
- W6722010866 via openalex
- W181246642 via openalex
- W7073584712 via openalex
- W1963985477 via openalex
- W1992764301 via openalex
Source provenance
- europepmc
- last seen: 2026-09-16T06:11:32.772430+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:20:13.663096+00:00
- unpaywall
- last seen: 2026-09-16T06:28:21.314993+00:00
License: CC0
· commercial use OK